- Volume is elevated versus the 13-week average, confirming attention.
R2AR34
SAO
Week ended 21 Aug 2026
Weekly Investor Report
Ultragenyx Pharmaceutical Inc. · Healthcare · Biotechnology
Latest close
13.46 BRL
4.6%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is - below the Trend Line and sits at 25.1% of its 52-week range. The latest completed week returned 4.6%, after a -15.7% four-week move. The latest news-sentiment score is 47/100.
Setup score
32
out of 100
Latest Close
13.46 BRL
21 Aug 2026
1W Return
4.6%
latest completed week
4W Return
-15.7%
short-term follow-through
12W Return
-
quarterly tape
Trend Breadth
0.0%
0 of 11 weeks active
Volume Ratio
8.2x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Next-week expectancy is negative at 33.94% based on similar historical setup states.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
4.6%
Latest completed week; four-week move -15.7%.
Indicator stack
0/50
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 33.94%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
47/100
8 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is - below the Trend Line and sits at 25.1% of its 52-week range. The latest completed week returned 4.6%, after a -15.7% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 8.2x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
14 Aug
21 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0212-week average 0.01
12-week confirmation
Trend active0/11Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/11Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/11Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.02Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers
No recent accumulation markers. 2 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -15.7% over four weeks, - over 12 weeks, and - over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.00Latest activity-pressure read.
Pressure change-Four-week change in activity pressure.
Leadership-Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
A published fundamentals and factor snapshot is not available for this company.
No published fundamental snapshot is available for this company.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment47/100
Weighted news tone is neutral across 8 relevant articles.
1 positive · 5 neutral · 2 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-24.6%Distance below the 52-week high.
13-week volatility15.4%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
12 Jun
10 Jul
7 Aug
21 Aug
Weeks higher4 of 102 weeks finished lower.
Best week+42.5%Week of 3 Jul.
Worst week-21.4%Week of 31 Jul.
Latest week+4.6%Week of 21 Aug.
Shape of recent returns
Strong gains3
Modest gains1
Flat weeks4
Modest losses0
Sharp losses2
Recent vol15.4%13-week weekly-return volatility.
Base vol15.4%52-week weekly-return volatility.
Up/down split4/2Count of positive and negative weeks in the 52-week window.
Average skew13.5% / -16.0%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorBR Healthcare
4-week rank78 / 82
Group average8.3%
Trend breadth39.0%
Trend39.0%active weekly trend signals
MD74.4%positive activity pressure
RS52.4%positive relative leadership
Four-week leaders
IndustryBR Biotechnology
4-week rank13 / 13
Group average24.1%
Trend breadth38.5%
Trend38.5%active weekly trend signals
MD76.9%positive activity pressure
RS69.2%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape32/100
Trend, activity pressure, participation, and risk combine to a 32/100 tape read.
Indicator analysis5/100Latest 12-week confirmation: trend 0/11, activity pressure 0/11, relative leadership 0/11.
Activity pressure 0.02; 2 reversal markers Next-Week ExpectancyNegative 33.94%Next-week expectancy is negative with a 33.94% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors50/100No published factor snapshot is available yet.
Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment47/100Weighted news tone is neutral across 8 relevant articles.
Ultragenyx Pharmaceutical Number of Employees 2026 | Employee Count & Headcount Data Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 21 Aug 2026 | 13.46 BRL | 4.6% | - | 14.05 BRL | 0.00 | - | 222 | Off |
| 14 Aug 2026 | 12.87 BRL | 0.0% | - | 14.11 BRL | 0.00 | - | 0 | Off |
| 7 Aug 2026 | 12.87 BRL | 2.6% | - | 14.25 BRL | 0.00 | - | 1 | Off |
| 31 Jul 2026 | 12.54 BRL | -21.4% | - | 14.42 BRL | 0.00 | - | 70 | Off |
| 24 Jul 2026 | 15.96 BRL | 0.0% | - | 14.69 BRL | 0.00 | - | 0 | Off |
| 17 Jul 2026 | 15.96 BRL | -10.5% | - | 14.47 BRL | 0.00 | - | 0 | Off |
| 10 Jul 2026 | 17.84 BRL | 4.4% | - | 14.18 BRL | 0.00 | - | 0 | Off |
| 3 Jul 2026 | 17.08 BRL | 42.5% | - | 13.26 BRL | 0.00 | - | 0 | Off |
| 26 Jun 2026 | 11.99 BRL | 0.0% | - | 11.99 BRL | - | - | 0 | Off |
| 19 Jun 2026 | 11.99 BRL | 0.0% | - | 11.99 BRL | - | - | 0 | Off |
| 12 Jun 2026 | 11.99 BRL | - | - | 11.99 BRL | - | - | 5 | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.